ArticleTranslational oncology2026

Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer.

Anas Gazzah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.